Adjuvant everolimus after renal cell carcinoma nephrectomy

被引：0
作者：
Feng, Yao-Ning [1 ]
Xiao, Li [2 ]
Xie, Guang-Yu [1 ]
机构：
[1] First Peoples Hosp Nanning, Urol Surg Dept, Nanning 530012, Peoples R China
[2] First Peoples Hosp Nanning, Dept Crit Care Med, Nanning 530012, Peoples R China
来源：
LANCET | 2024年 / 404卷 / 10465期
关键词：
RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1809 / 1810
页数：2
相关论文
共 5 条
  • [1] Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
    Haas, Naomi B.
    Manola, Judith
    Dutcher, Janice P.
    Flaherty, Keith T.
    Uzzo, Robert G.
    Atkins, Michael B.
    DiPaola, Robert S.
    Choueiri, Toni K.
    [J]. JAMA ONCOLOGY, 2017, 3 (09) : 1249 - 1252
  • [2] Mo Dun-Chang, 2023, Lancet Oncol, V24, pe230, DOI 10.1016/S1470-2045(23)00211-5
  • [3] Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
    Pal, Sumanta Kumar
    Uzzo, Robert
    Karam, Jose Antonio
    Master, Viraj A.
    Donskov, Frede
    Suarez, Cristina
    Albiges, Laurence
    Rini, Brian
    Tomita, Yoshihiko
    Kann, Ariel Galapo
    Procopio, Giuseppe
    Massari, Francesco
    Zibelman, Matthew
    Antonyan, Igor
    Huseni, Mahrukh
    Basu, Debasmita
    Ci, Bo
    Leung, William
    Khan, Omara
    Dubey, Sarita
    Bex, Axel
    [J]. LANCET, 2022, 400 (10358) : 1103 - 1116
  • [4] Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    George, D. J.
    Pantuck, A. J.
    Patel, A.
    Chang, Y. -H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lechuga, M.
    Lin, X.
    Martini, J. -F.
    Ramaswamy, K.
    Casey, M.
    Staehler, M.
    Patard, J. -J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23) : 2246 - 2254
  • [5] Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
    Ryan, Christopher W.
    Tangen, Catherine M.
    Heath, Elisabeth, I
    Stein, Mark N.
    Meng, Maxwell, V
    Alva, Ajjai S.
    Pal, Sumanta K.
    Puzanov, Igor
    Clark, Joseph, I
    Choueiri, Toni K.
    Agarwal, Neeraj
    Uzzo, Robert G.
    Haas, Naomi B.
    Synold, Timothy W.
    Plets, Melissa
    Vaishampayan, Ulka N.
    Shuch, Brian M.
    Thompson Jr, Ian M.
    Lara Jr, Primo N.
    [J]. LANCET, 2023, 402 (10407) : 1043 - 1051
1